Nephrocare Health Services share price today

Nephrocare Health Services Ltd's share price was ₹622.35 at the close on 4 November 2026. It has been rising for 41 weeks. That is 0.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Nephrocare Health Services Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 19 December 2025, it has traded between ₹449 and ₹765, and at that close it sat 55% of the way up from that low.

Over the last 11 months the share price moved +39% while the NIFTY 500 moved −8%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

5 points in one quarter.

1. Promoters cut their stake by 5.5 points in one quarter

   From 63.9% to 58.3% in the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Nephrocare Health Services reported revenue of ₹282 crore, up 23.7% from ₹228 crore a year earlier, and a profit of ₹32.0 crore, up 33.3% from ₹24.0 crore.

Nephrocare Health Services results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Nephrocare Health Services' management discussed these results on a call held on 12 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Nephrocare Health Services closed at ₹622.35 on 4 November 2026, up 38.6% from ₹449.15 a year earlier (19 December 2025). Its highest weekly close since December 2025 was ₹765.35 on 11 September 2026.

Nephrocare Health Services share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

55 weekly closes from 19 December 2025 to 4 November 2026.

4 Nov 2026: Nephrocare Health Services closed at ₹622.35, up 1.3% on the week and down 4.1% on the month. 12 Aug 2026: Nephrocare Health Services held its results call for April to June 2026. Management guided: Medium-term revenue growth of 15-20% over the next 3-5 years.

Earlier

• Results for April to June 2026: Revenue up 23.7% and profit up 33.3% on a year earlier.

Nephrocare Health Services has paid no dividend on the NSE since its first NSE close in our records (19 December 2025), the start of the period we checked.

No. Nephrocare Health Services Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 12 August 2026, Nephrocare Health Services' management guided: Medium-term revenue growth of 15-20% over the next 3-5 years.

“We will not pursue business that does not meet our return thresholds.”Rohit Singh, on the call for April to June 2026

What management guided

• India clinic additions of 40-50 annually and Philippines additions of 10-15 annually.
• New international market launch every 12-18 months.
• NIDA first training batch begins in Q3.
• Saudi formal tendering expected to begin in 2 months.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 12 August 2026.

When Nephrocare Health Services reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Philippines additions - check integration, operating contribution and utilization progression across the acquired centers.

Nephrocare Health Services is not on any of our India lists this week.

Nephrocare Health Services Ltd earned ₹32.0 Cr of net profit in the Jun 2026 quarter, +33.3% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹77.0 Cr. Over 5 years profit has grown 138.4% a year on average. That is 11.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹24.0 Cr.

For the full year, FY26 profit was ₹77.0 Cr (+14.9% on the year before).

Why profit moved: revenue changed +23.7% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +37.8% and revenue +25.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Nephrocare Health Services Ltd reported ₹282 Cr of revenue in the Jun 2026 quarter, +23.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 28.4% a year on average. The last full year, FY26, came in at ₹999 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,054 Cr.

FY26 revenue was ₹999 Cr, +32.1% on the year before.

Recent pace: the last four quarters grew +25.7% on average, against 28.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Nephrocare Health Services Ltd's operating margin was 21.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 6 years it has been between 5.0% and 23.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.5 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 246% of Nephrocare Health Services Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹233 Cr of operating cash against ₹77.0 Cr of profit. After ₹212 Cr of spending on assets, ₹21.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 246% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 2.1× depreciation over three years. The next section checks what that spending is building.

Nephrocare Health Services Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 116 days in FY26, up from 110 days in FY21. It spent ₹469 Cr on assets over the last 3 years. Customers take 116 days to pay, and stock sits for 53 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹999 Cr, each day of that cycle ties up about ₹2.7 Cr, so roughly ₹317 Cr is tied up in the business at any time.

FY26: customers took 116 days to pay and stock sat for 53 days, about 1.7 months of sales sitting as stock, for a full cycle of 116 days, longer than FY21's 110.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 53 days. Customers pay about 116 days after that. Suppliers are paid at 230 days. Together that makes the 116-day cycle.

Spending on assets: ₹469 Cr over the last 3 years, against ₹219 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹6.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Nephrocare Health Services Ltd's P/E is 73.5×, near the low end of its own history: it has been lower only 13% of the time. Its usual P/E (the middle reading) is 82.1×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved −88.1% while the price moved +38.6%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Nephrocare Health Services Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Nephrocare Health Services Ltd earned a ROCE of 15% in FY26. That is up from a low of −4% in FY22. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.7% net margin and 0.68× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 7.7% net margin × 0.68× asset turnover × 1.31× leverage (assets divided by equity) ≈ 6.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 15.8% − 12.0% = +3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

Nephrocare Health Services Ltd has total debt of ₹80.0 Cr against shareholder equity of ₹1,116 Cr as of Jun 2026, so its debt is 0.07× its equity, which is very little. Year by year, that ratio went from 0.44 in FY25 to 0.07 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of Nephrocare Health Services Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For Nephrocare Health Services Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

47.9 out of 100, rank 4 of 7 in Hospitals/Medical Services, with 55% of the evidence available.

Nephrocare Health Services Ltd scores 47.9 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 4. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 25.6 + 9.5 + 12.8 = 47.9 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Nephrocare Health Services ranks 4 of 7 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 47.9 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals/Medical Services, all 7 compared on one page.

Nephrocare Health Services is the 3rd largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Agarwals Health Care and Park Medi World. Just below it: Gujarat Kidney & Super Speciality, Unihealth Hospitals, Gaudium IVF and Women Health and KRM Ayurveda.

Hospitals/Medical Services companies close in size

1. Dr Agarwals Health Care Ltd ₹16,144 crore
2. Park Medi World Ltd ₹9,490 crore
3. Nephrocare Health Services Ltd ₹6,180 crore
4. Gujarat Kidney & Super Speciality Ltd ₹1,288 crore
5. Unihealth Hospitals Ltd ₹875 crore
6. Gaudium IVF and Women Health Ltd ₹771 crore
7. KRM Ayurveda Ltd ₹479 crore

All 7 Hospitals/Medical Services companies, largest first

Companies close in size in other industries

757. Morepen Laboratories Ltd ₹6,211 crore · Pharma - API & CRAMS
758. Marine Electricals (India) Ltd ₹6,192 crore · Shipping - Proxy
759. Nephrocare Health Services Ltd ₹6,180 crore
760. Shrem InvIT ₹6,176 crore · Infrastructure Investment Trusts
761. Waterways Leisure Tourism Limited ₹6,166 crore

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.